Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

Cytokine networks demonstrate dual functionality. Cytokines are key regulators of immune homeostasis, but paradoxically, cytokines also function as pathogenic drivers in diseases such as systemic ...

Giant cell arteritis (GCA) is the most frequent primary systemic vasculitis in adults, involving medium-to-large-sized ...

Icotrokinra is designed to selectively block the IL-23 receptor, which drives inflammation in plaque psoriasis and ...

Abivax dazzled investors and analysts with positive data from a pair of Phase III induction trials assessing obefazimod in adults with moderately to severely active ulcerative colitis. The results ...

Icotrokinra is a first-in-class targeted oral peptide that blocks interleukin (IL) 23 and its receptor, which plays a key ...

Johnson & Johnson eyes FDA nod to icotrokinra after phase III studies show strong skin clearance and safety in plaque ...

There was a lot of excitement when Tepezza became the first drug approved for the treatment of thyroid eye disease in January ...

Icotrokinra was jointly discovered and is being developed pursuant to the license and collaboration agreement between ...

YourChoice Therapeutics, a biotech company based in California, has reported promising safety data from an early-stage ...

Dupilumab in combination with other biologic agents is safe and effective for treating various chronic inflammatory conditions.

Obefazimod’s strong Phase 3 induction data positions Abivax as leading UC contender with novel mechanism and favorable safety ...